These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34164187)

  • 1. Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis.
    Hu R; Zhao Z; Shi Y; Shi M; Xia G; Yu S; Feng J
    J Thorac Dis; 2021 May; 13(5):2959-2967. PubMed ID: 34164187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection.
    Zhao Z; Hu R; Chen Y; Zhou G; Yu S; Feng J
    Oncol Res Treat; 2022; 45(6):366-374. PubMed ID: 35231913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study.
    Wan C; Zhang Y; Liu P; Mei X; Cheng G; Pang J; Chen S; Xu J; Malhotra J; Qian H; Du Y
    J Thorac Dis; 2023 Oct; 15(10):5648-5657. PubMed ID: 37969256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study.
    Huang Z; Zhou C; Xiong Y; Yang F; Zeng F; Jiang W; Zhang Y; Yang H; Liu L; Zeng L; Yang N; Wang Z
    Front Oncol; 2022; 12():909721. PubMed ID: 36439441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
    Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional bevacizumab in EGFR-mutant lung adenocarcinoma patients who had oligo-progression after the failure of EGFR-TKI: A single-institute retrospective study.
    Kashiwabara K; Fujii S; Tsumura S; Sakamoto K; Semba H
    Cancer Treat Res Commun; 2020; 22():100163. PubMed ID: 31675534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world study of PD-1/L1 immune checkpoint inhibitors for advanced non-small cell lung cancer after resistance to EGFR-TKIs.
    Wei K; Zhou C; Chen Y; Feng X; Tang H
    Front Oncol; 2023; 13():1217872. PubMed ID: 37534246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure.
    Lam TC; Tsang KC; Choi HC; Lee VH; Lam KO; Chiang CL; So TH; Chan WW; Nyaw SF; Lim F; Lau JO; Chik J; Kong FM; Lee AW
    Lung Cancer; 2021 Sep; 159():18-26. PubMed ID: 34303276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure.
    Li M; Lin C; Lin J; Chen S; Weng L; He Z
    Oncol Lett; 2024 Nov; 28(5):504. PubMed ID: 39233818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
    Kang M; Park C; Kim SH; Yoon SW; Suh KJ; Kim YJ; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
    Transl Lung Cancer Res; 2021 Feb; 10(2):699-711. PubMed ID: 33718015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC.
    Liu S; Wu F; Li X; Zhao C; Jia Y; Jia K; Han R; Qiao M; Li W; Yu J; Zhou F; Xiong A; Chen B; Fan J; Ren S; Zhou C
    Front Oncol; 2021; 11():639947. PubMed ID: 33777802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma.
    Zhou CZ; Qin YY; Xie ZH; Zhang JX; Ou-Yang M; Li SY; Chen RC
    Chin J Cancer Res; 2014 Dec; 26(6):705-10. PubMed ID: 25561769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study.
    Hsu PC; Huang CY; Wang CC; Kuo SC; Chu CH; Tung PH; Huang AC; Wang CL; Chiu LC; Fang YF; Yang CT
    Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33113888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.
    Su S; Dong ZY; Xie Z; Yan LX; Li YF; Su J; Liu SY; Yin K; Chen RL; Huang SM; Chen ZH; Yang JJ; Tu HY; Zhou Q; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Nov; 13(11):1668-1675. PubMed ID: 30056164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.
    Hong L; Lewis WE; Nilsson M; Patel S; Varghese S; Rivera MJ; Du RR; Chen P; Kemp HN; Rinsurongkawong W; Heeke S; Spelman AR; Elamin YY; Negrao MV; Sepesi B; Gibbons DL; Lee JJ; Wu J; Vokes NI; Heymach JV; Zhang J; Le X
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.